Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies-Reference-Cited by-同舟云学术

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Published:2022-11-03 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Liu Xiaoqiang¹,Park Juliana²,Xia Shengli³,Liang Bin⁴,Yang Shuangmin¹,Wang Yanxia³,Syrkina Olga⁵,Lavis Nathalie⁶,Liu Shuzhen⁷,Zhao Chenyan⁷,Ding Jian⁴,Hu Jieqiong²,Samson Sandrine I.⁶,de Bruijn Iris A.⁸,

Affiliation:

1. Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, China

2. Global Clinical Development, Sanofi, Sydney, Australia

3. Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, China

4. China Medical, Sanofi, Beijing, China

5. Global Pharmacovigilance, Sanofi, Swiftwater, Pennsylvania, USA

6. Global Medical, Sanofi, Lyon, France

7. Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China

8. Global Clinical Development, Sanofi, Marcy l’Etoile, France

Funder

Sanofi

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link